X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RL-007
Therapeutic Area: Psychiatry/Psychology Product Name: FSV7-007
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 12, 2021
Details:
Recognify's lead compound, "RL-007", previously called FSV7-007, has exhibited a modulating effect on three mechanisms that are central to learning and memory: the cholinergic, NMDA and GABA type B receptor systems.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Investment Group
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 23, 2020
Details:
Proceeds from the financing will be used primarily to fund pre-clinical and clinical development of ATAI's existing mental health programs, to expand its drug candidate pipeline and further advance ATAI's platform technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI 425809
Therapeutic Area: Psychiatry/Psychology Product Name: BI 425809
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
